ES2838573T3 - Derivados de benzamida ligados como inhibidores potentes de ROCK - Google Patents

Derivados de benzamida ligados como inhibidores potentes de ROCK Download PDF

Info

Publication number
ES2838573T3
ES2838573T3 ES15756322T ES15756322T ES2838573T3 ES 2838573 T3 ES2838573 T3 ES 2838573T3 ES 15756322 T ES15756322 T ES 15756322T ES 15756322 T ES15756322 T ES 15756322T ES 2838573 T3 ES2838573 T3 ES 2838573T3
Authority
ES
Spain
Prior art keywords
substituted
independently selected
methoxy
pyrazol
benzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15756322T
Other languages
English (en)
Spanish (es)
Inventor
Zilun Hu
Doree F Sitkoff
Mimi L Quan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2838573T3 publication Critical patent/ES2838573T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES15756322T 2014-08-21 2015-08-20 Derivados de benzamida ligados como inhibidores potentes de ROCK Active ES2838573T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462040044P 2014-08-21 2014-08-21
PCT/US2015/046032 WO2016028971A1 (en) 2014-08-21 2015-08-20 Tied-back benzamide derivatives as potent rock inhibitors

Publications (1)

Publication Number Publication Date
ES2838573T3 true ES2838573T3 (es) 2021-07-02

Family

ID=54011128

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15756322T Active ES2838573T3 (es) 2014-08-21 2015-08-20 Derivados de benzamida ligados como inhibidores potentes de ROCK

Country Status (6)

Country Link
US (1) US10112939B2 (enExample)
EP (1) EP3183248B1 (enExample)
JP (1) JP6633618B2 (enExample)
CN (1) CN107108581B (enExample)
ES (1) ES2838573T3 (enExample)
WO (1) WO2016028971A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6779214B2 (ja) 2015-01-09 2020-11-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての環状ウレア
EP3268360B1 (en) 2015-03-09 2019-04-24 Bristol-Myers Squibb Company Lactams as inhibitors of rock
CN106924254A (zh) * 2015-12-31 2017-07-07 中国医学科学院药物研究所 黄连碱在制备预防和/或治疗系统性红斑狼疮及其并发症药物中的应用
UY37073A (es) 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen
ES2781309T3 (es) 2016-05-27 2020-09-01 Bristol Myers Squibb Co Triazolonas y tetrazolonas como inhibidores de ROCK
WO2018009622A1 (en) 2016-07-07 2018-01-11 Bristol-Myers Squibb Company Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors
EP3481828B1 (en) 2016-07-07 2020-09-16 Bristol-Myers Squibb Company Spiro-fused cyclic ureas as inhibitors of rock
KR102491994B1 (ko) 2016-07-07 2023-01-25 브리스톨-마이어스 스큅 컴퍼니 Rock의 억제제로서의 스피로락탐
ES2829400T3 (es) 2016-11-30 2021-05-31 Bristol Myers Squibb Co Inhibidores tricíclicos de Rho cinasa
CN108203433B (zh) * 2016-12-16 2020-07-03 成都先导药物开发股份有限公司 一种rock抑制剂及其应用
AU2018294054B2 (en) * 2017-06-30 2022-05-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
TW201908293A (zh) 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
EP3652164B1 (en) 2017-07-12 2023-06-21 Bristol-Myers Squibb Company Phenylacetamides as inhibitors of rock
KR102644889B1 (ko) 2017-07-12 2024-03-06 브리스톨-마이어스 스큅 컴퍼니 Rock 억제제로서의 스피로헵타닐 히단토인
US12060341B2 (en) 2017-07-12 2024-08-13 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as ROCK inhibitors
EP3652165B1 (en) 2017-07-12 2021-08-25 Bristol-Myers Squibb Company Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure
WO2019089868A1 (en) 2017-11-03 2019-05-09 Bristol-Myers Squibb Company Diazaspiro rock inhibitors
US11345678B2 (en) 2018-04-18 2022-05-31 Medshine Discovery Inc. Benzopyrazole compound used as RHO kinase inhibitor
US11702400B2 (en) 2019-10-18 2023-07-18 Medshine Discovery Inc. Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors
CN114262322B (zh) * 2020-09-16 2026-01-06 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
WO2022100614A1 (zh) * 2020-11-11 2022-05-19 南京明德新药研发有限公司 苯并脲环衍生物及其制备方法和应用
US20250000083A1 (en) 2021-11-11 2025-01-02 The Doshisha Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0259559A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ピリドン誘導体又はその塩類
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
EP0716650B1 (en) 1993-09-03 1999-03-24 Smithkline Beecham Plc Indole and indoline derivatives as 5ht1d receptor antagonists
WO1995011243A1 (en) * 1993-10-19 1995-04-27 Smithkline Beecham Plc Benzanilide derivatives as 5ht-1d receptor antagonists
CA2338697A1 (en) * 1998-07-28 2000-02-10 Smithkline Beecham Corporation Compounds and methods
CA2340100A1 (en) 1998-08-11 2000-02-24 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
TR200103214T2 (tr) * 1999-05-04 2002-03-21 Schering Corporation CCR5 antagonistleri olarak yararlì piperazin trevleri.
CN1481377A (zh) * 2000-03-17 2004-03-10 ����˹�ж�-����˹˹����ҩƷ��˾ 作为基质金属蛋白酶和TNF-α的抑制剂的环β-氨基酸衍生物
GB2361003A (en) 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
IL160990A0 (en) 2001-10-01 2004-08-31 Bristol Myers Squibb Co Spiro-hydantoin compounds useful as anti-inflammatory agents
AR038420A1 (es) * 2002-02-15 2005-01-12 Glaxo Group Ltd Compuesto de amida, procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
TWI319387B (en) * 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
WO2004011440A1 (ja) 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
RU2005118407A (ru) 2002-12-13 2006-03-10 СмитКлайн Бичем Корпорейшн (US) Производные пиперидина в качестве антагонистов ccr5
WO2004056774A2 (en) * 2002-12-19 2004-07-08 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
RS53118B (sr) 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
EP1599475A2 (en) 2003-03-06 2005-11-30 Eisai Co., Ltd. Jnk inhibitors
EP1713775A4 (en) * 2004-01-30 2009-08-12 Smithkline Beecham Corp CHEMICAL COMPOUNDS
CN1960969B (zh) * 2004-04-01 2012-03-28 伊莱利利公司 组胺h3受体药物、其制备方法及治疗用途
DK1882684T3 (en) 2005-05-19 2015-01-05 Astellas Pharma Inc PYRROLIDE INGREDIENTS OR SALTS THEREOF
KR20080016659A (ko) 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
WO2007002563A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
GB0514812D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
JP2009523812A (ja) * 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
TW200808751A (en) 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
PL2090570T3 (pl) 2006-09-05 2012-03-30 Kyowa Hakko Kirin Co Ltd Pochodna imidazolu
ES2729424T3 (es) 2006-09-20 2019-11-04 Aerie Pharmaceuticals Inc Inhibidores de Rho cinasa
CL2007003874A1 (es) 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
MX2009011578A (es) 2007-04-25 2009-11-11 Exelixis Inc 6-fenilpirimidinonas como moduladores de pim.
BRPI0815658A2 (pt) 2007-08-07 2015-02-18 Hoffmann La Roche Aril-éter pirrolidina como antagonistas do receptor nk3
CA2697382A1 (en) * 2007-08-27 2009-03-05 Abbott Gmbh & Co. Kg 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
WO2009073545A2 (en) 2007-11-30 2009-06-11 Maxthera, Inc. Tetrahydro-isoquinoline ppat inhibitors as antibacterial agents
WO2009072643A1 (en) * 2007-12-03 2009-06-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof
BRPI0914779A2 (pt) 2008-06-16 2015-10-20 Hoffmann La Roche derivados de pirrolidina como antagonistas de receptor de nk2
US20110118262A1 (en) 2008-07-08 2011-05-19 Boehringer Ingelheim International Gmbh Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
US8609690B2 (en) 2008-08-25 2013-12-17 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
AU2009301212A1 (en) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Pyrrolidine n-benzyl derivatives
EP2375904B1 (en) * 2008-12-09 2014-05-28 Merck Sharp & Dohme Corp. Biaryl carboxamides
EP2379524A1 (en) * 2008-12-18 2011-10-26 Boehringer Ingelheim International GmbH Serotonin 5-ht2b receptor inhibitors
AU2010209825A1 (en) 2009-01-30 2011-08-11 F. Hoffmann-La Roche Ag Piperidine derivatives as NK3 receptor antagonists
US8324250B2 (en) 2009-03-19 2012-12-04 Hoffmann-La Roche Inc. Piperidine derivatives as NK3 receptor antagonists
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
EP2435046B1 (en) * 2009-05-28 2013-09-04 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compounds for the treatment of stress-related conditions
TW201103904A (en) * 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
JP6267863B2 (ja) 2009-10-16 2018-01-24 メリンタ セラピューティクス，インコーポレイテッド 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
LT2513053T (lt) 2009-12-18 2018-01-25 Ogeda Sa Pirolidino karboksirūgščių dariniai kaip su g baltymu sąveikaujančio receptoriaus 43 (gpr43) agonistai, farmacinės kompozicijos ir būdai, skirti naudoti metabolinių susirgimų gydymui
UY33199A (es) 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.
US8507535B2 (en) 2010-07-07 2013-08-13 Hoffmann-La Roche Inc. Methyl-pyrrolidine ether derivatives
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
MX2013005454A (es) 2010-11-15 2013-06-24 Abbvie Inc Inhibidores de nampt y rock.
UA114406C2 (uk) * 2011-08-09 2017-06-12 Такеда Фармасьютікал Компані Лімітед Похідні циклопропанаміну як інгібітори lsd1
SG11201406518XA (en) 2012-04-12 2014-11-27 Univ Leland Stanford Junior Substituted benzamides and their uses
WO2013153539A1 (en) * 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
BR112014032581A8 (pt) 2012-06-27 2018-08-14 4Sc Discovery Gmbh inibidores de bifluorodioxalano-amino-benzimidazol quinase para o tratamento de câncer, distúrbios do snc e inflamação autoimune
JP6109934B2 (ja) * 2012-07-03 2017-04-05 ３−ブイ・バイオサイエンシーズ・インコーポレイテッド３−Ｖ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 脂質合成の複素環モジュレーター
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
CN103664878A (zh) 2012-09-12 2014-03-26 山东亨利医药科技有限责任公司 杂芳环及其衍生物类酪氨酸激酶抑制剂
EP2903618B1 (en) 2012-10-05 2022-06-01 Kadmon Corporation, LLC Rho kinase inhibitors
SMT202000713T1 (it) * 2012-12-07 2021-03-15 Vertex Pharma Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
WO2014113620A2 (en) 2013-01-18 2014-07-24 Bristol-Myers Squibb Company Phthalazinones and isoquinolinones as rock inhibitors
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors

Also Published As

Publication number Publication date
JP6633618B2 (ja) 2020-01-22
CN107108581A (zh) 2017-08-29
US20170226105A1 (en) 2017-08-10
US10112939B2 (en) 2018-10-30
CN107108581B (zh) 2020-06-23
EP3183248A1 (en) 2017-06-28
WO2016028971A1 (en) 2016-02-25
EP3183248B1 (en) 2020-11-11
JP2017524026A (ja) 2017-08-24

Similar Documents

Publication Publication Date Title
ES2814325T3 (es) Derivados de lactama, urea cíclica y carbamato y de triazolona como inhibidores potentes y selectivos de ROCK
ES2937039T3 (es) Inhibidores diazaespiro de ROCK
US10112939B2 (en) Tied-back benzamide derivatives as potent rock inhibitors
ES2821877T3 (es) Espirolactamas como inhibidores de ROCK
ES2684776T3 (es) Ftalazinonas e isoquinolinonas como inhibidores de ROCK
ES2781309T3 (es) Triazolonas y tetrazolonas como inhibidores de ROCK
EP2961745B1 (en) Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
ES2634628T3 (es) Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK
ES2730112T3 (es) Lactamas como inhibidores de ROCK
ES2815681T3 (es) Ureas cíclicas como inhibidores de ROCK
CN105102448B (zh) 作为rock1和rock2抑制剂的苯基吡唑衍生物
EP3481828A1 (en) Spiro-fused cyclic ureas as inhibitors of rock
ES2894128T3 (es) Inhibidores aminoheterocíclicos de cinco miembros y aminoheterocíclicos bicíclicos de 5,6 o 6,6 miembros de ROCK para el tratamiento de la insuficiencia cardíaca